Group 1 - The core point of the article is that Zai Lab Limited (荃信生物-B) has seen its stock price increase by over 5% following the announcement of a licensing deal worth up to $700 million for the TSLPxIL-13 dual antibody drug with a subsidiary of Windward [1] - This marks the third overseas transaction for the company this year, following previous agreements granting global rights for QX030N to Caldera and licensing QX031N to Roche [1] - Zhongyou Securities highlights that the company is a leader in the domestic autoimmune innovative drug sector, with a solid foundation in this field [1] Group 2 - The company's mature pipeline is entering a monetization phase, enhancing its capital-raising capabilities [1] - The continuous overseas licensing of innovative pipelines provides further assurance for the company's stable operations [1] - Huachuang Securities expresses optimism about the company's ability to maintain its leading position in the autoimmune sector [1]
荃信生物-B涨超5% 三款长效双抗顺利出海 机构看好公司在自免领域领先地位